Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3208559 | 0.99 | DPP4 (0.60) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3186723 | 0.90 | DPP4 (0.60) | DPP4DPP8DPP9 | |
| SCHEMBL5548643 | 0.83 | DPP4 (0.64) | DPP4DPP8DPP9 | |
| SCHEMBL5548464 | 0.83 | DPP4 (0.64) | DPP4DPP8DPP9 | |
| SCHEMBL5549234 | 0.83 | DPP4 (0.64) | DPP4DPP8DPP9 | |
| SCHEMBL5543300 | 0.83 | DPP4 (0.64) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5548351 | 0.83 | DPP4 (0.63) | DPP4DPP8DPP9 | |
| SCHEMBL4713257 | 0.80 | DPP4 (0.60) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3208550 | 0.79 | DPP4 (0.59) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3195546 | 0.77 | DPP4 (0.97) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-1323710-B1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | DPP4 4248/4885DPP8 4539/4885DPP9 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.